Veterinary medicines and competition animals: The question of medication versus doping control

Handbook of Experimental Pharmacology

Volumn 199, Issue , 2010, Pages 315-339

  Toutain, Pierre Louis ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Detection time; Doping; Horse; Irrelevant urine plasma concentration; Medication control; Risk analysis; Threshold; Withdrawal time

Indexed keywords

ANABOLIC AGENT; BOLDENONE; BUFOTENINE; CENTRAL STIMULANT AGENT; CIMETIDINE; DRUG METABOLITE; FLUNIXIN; FUROSEMIDE; GROWTH FACTOR; HORDENINE; HYDROCORTISONE; KETOPROFEN; LEVAMISOLE; MECLOFENAMIC ACID; NANDROLONE; NONSTEROID ANTIINFLAMMATORY AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMEPRAZOLE; PHENYLBUTAZONE; PROCAINE PENICILLIN; PSYCHOSTIMULANT AGENT; RANITIDINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN; STANOZOLOL; TESTOSTERONE; TRANQUILIZER; UNINDEXED DRUG; VETERINARY DRUG;

ANALYTIC METHOD; ANIMAL CARE; ANIMAL HEALTH; ANIMAL WELFARE; BLOOD ANALYSIS; DECISION MAKING; DOPING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG LEGISLATION; DRUG SCREENING; DRUG TOLERANCE; DRUG URINE LEVEL; DRUG WITHDRAWAL; HORSE; INTERMETHOD COMPARISON; MASS FRAGMENTOGRAPHY; METABOLOMICS; MOLECULAR BIOLOGY; NONHUMAN; PHARMACODYNAMICS; PHYSICAL PERFORMANCE; POLICY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; URINALYSIS; VETERINARY MEDICINE; ANIMAL; ANIMAL DISEASE; BLOOD; DRUG THERAPY; FRANCE; LEGAL ASPECT; SAFETY; STANDARD; STATISTICS; URINE;

ANIMAL DISEASES; ANIMALS; BLOOD CHEMICAL ANALYSIS; DOPING IN SPORTS; DRUG THERAPY; FRANCE; HORSES; RISK ASSESSMENT; SAFETY; URINALYSIS; VETERINARY MEDICINE;

EID: 77953665121     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-10324-7_13     Document Type: Review

References (48)

1. Aguilera R, Becchi M, Mateus L, Popot MA, Bonnaire Y, Casabianca H, Hatton CK (1997) Detection of exogenous hydrocortisone in horse urine by gas chromatography-combustion-carbon isotope ratio mass spectrometry. J Chromatogr B Biomed Sci Appl 702:85-91
2. Authié E, Garcia P, Popot MA, Toutain PL, Doucet MY (2009) Effect of an endurance-like exercise on the disposition and detection time of phenylbutazone and dexamethasone in the horse: application to medication control. Equine Vet J (in press)
3. Bailly-Chouriberry L, Chu-Van E, Pinel G, Garcia P, Popot MA, Andre-Fontaine G, Bonnaire Y, Le Bizec B (2008a) Detection of secondary biomarker of met-eGH as a strategy to screen for somatotropin misuse in horseracing. Analyst 133:270-276
4. Bailly-Chouriberry L, Pinel G, Garcia P, Popot MA, Le Bizec B, Bonnaire Y (2008b) Identification of recombinant equine growth hormone in horse plasma by LC-MS/MS: a confirmatory analysis in doping control. Anal Chem 80:8340-8347
5. Barragry T (2006) Continuing education-Doping and drug detection times in horses: new data for therapeutic agents. Irish Vet J 59:394-398
6. de Kock SS, Boshoff R, Jogi P, Swanepoel BC (2004) An investigation of performance enhancing drug use in pigeon racing and the development of suitable faeces testing methodology. In: Albert PH, Morton T, Wade JF (eds) 15th International Conference of Racing Analysts and Veterinarians. R&W Communications, Dubai, UAE, pp 359-364
7. Dunnett N (1994) Sampling procedure-sampling preparation (chain of custody). In: Kallings U, Bondesson U, Houghton E (eds) 10th International Conference of Racing Analysts and Veterinarians. R&W, Stockholm, Sweden, pp 313-315
8. Dunnett M, Lees P (2003) Trace element, toxin and drug elimination in hair with particular reference to the horse. Res Vet Sci 75:89-101
9. Guan F, Uboh CE, Soma LR, Birks E, Chen J, Mitchell J, You Y, Rudy J, Xu F, Li X, Mbuy G (2007) LC-MS/MS method for confirmation of recombinant human erythropoietin and darbepoetin alpha in equine plasma. Anal Chem 79:4627-4635
10. Hall DJ (2004) ISO/IEC 17025: a guide to interpretation within the AORC. In: Albert PH, Morton T, Wade JF (eds) 15th International Conference of Racing Analysts and Veterinarians. R&W Communications, Dubai, UAE, pp 199
11. Higgins AJ (2006) From ancient Greece to modern Athens: 3000 years of doping in competition horses. J Vet Pharmacol Ther 29:4-8
12. Hinchcliff KW, Muir WW III (1991) Pharmacology of furosemide in the horse: a review. J Vet Intern Med 5:211-218
13. Hinchcliff KW, Morley PS, Guthrie AJ (2009) Efficacy of furosemide for prevention of exerciseinduced pulmonary hemorrhage in thoroughbred racehorses. J Am Vet Med Assoc 235:76-82
14. Hodgson D, Howe S, Jeffcott L, Reid S, Mellor D, Higgins A (2005) Effect of prolonged use of altrenogest on behaviour in mares. Vet J 169:322-325
15. Houghton E (1994) The threshold values-current and future problems. In: Kallings P, Bondesson U, Houghton E (eds) 10th International Conference of Racing Analysts and Veterinarians. R&W, Stockholm, Sweden, pp 297-302
16. Houghton E, Crone DL (2000) The approaches adopted by the racing industry to address endogenous substances and substances of dietary origin. In: Williams RB, Houghton E, Wade JF (eds) 13th International Conference of Racing Analysts and Veterinarians. R&W, Cambridge, UK, pp 23-28
17. Houghton E, Williams RB, Toutain PL (2004) Therapeutic substances-The road to reform the European approach. In: Albert PH, Morton T, Wade JF (eds) 15th International Conference of Racing Analysts and Veterinarians. R&W Communications, Dubai, United Arab Emirates, pp 16-18
18. Lakhani KH, Lambert M, Sluyter F, Devolz R, Maylin G, Higgins AJ (2004) Estimation of the critical threshold value for presence of salicylic acid in the urine of thoroughbred horses. In: Albert PH, Morton T, Wade JF (eds) 15th International Conference of Racing Analysts and Veterinarians. R&W Communications, Dubai, United Arab Emirates, pp 67-77
19. Lees P, Taylor JB, Higgins AJ, Sharma SC (1986) Phenylbutazone and oxyphenbutazone distribution into tissue fluids in the horse. J Vet Pharmacol Ther 9:204-212
20. Lilliehook I, Schuback-Nosell K, Essen-Gustavsson B et al (2004) Haematological and bone marrow responses after administration of recombinant human arythropoietin (rhEPO) to horses. In: Albert PH, Morton T, Wade JF (eds) 15th International Conference of Racing Analysts and Veterinarians. R&W Communications, Dubai, United Arab Emirates, pp 509-513
21. McKeever KH (1996) Erythropoietin: a new formof blood doping in horses. In: Auer D, Houghton E (eds) 11th International Conference of Racing Analysts and Veterinarians. Queensland, Australia, pp 79-84
22. McKeever KH, Malinowski K, Christensen RA, Hafs HD (1998) Chronic recombinant equine somatotropin (eST) administration does not affect aerobic capacity or exercise performance in geriatric mares. Vet J 155:19-25
23. Norgren A, Ingvast-Larsson C, Kallings P, Fredriksson F, Bondesson U (2000) Contamination and urinary excretion of flunixin after repeated administration in the horse. In: Williams RB, Houghton E, Wade JF (eds) 13th International Conference of Racing Analysts and Veterinarians. R&W, Cambridge, UK, pp 377-380
24. Pascoe JR, McCabe AE, Franti CE, Arthur RM (1985) Efficacy of furosemide in the treatment of exercise-induced pulmonary hemorrhage in thoroughbred racehorses. Am J Vet Res 46: 2000-2003
25. Piercy RJ, Swardson CJ, Hinchcliff KW (1998) Erythroid hypoplasia and anemia following administration of recombinant human erythropoietin to two horses. J Am Vet Med Assoc 212:244-247
26. Popot MA, Houghton E, Ginn A, JonesM, Teale P, Samuels T, Lassourd V, Dunnett N, Cowan DA, Bonnaire Y, Toutain PL (1997) Cortisol concentrations in post competition horse urine: a French and British survey. Equine Vet J 29:226-229
27. Popot MA, Bobin S, Bonnaire Y, Monget P, Toquet MP, Fortier G, Delahaut P, Closset J (2000) Study related to the detection of recombinant equine growth hormone administration in the horse. In: Williams RB, Houghton WJF (eds) 13th International Conference of Racing Analysts and Veterinarians. Cambridge, UK
28. Popot MA, Stojiljkovic N, Garcia P, Richard CA, Bonnaire Y, Tabet JC (2002) Additional studies on the detection of drugs in horse hair samples. In: Hill D, Hill W (eds) 14th International Conference of Racing Analysts and Veterinarians. R&W, Orlando, USA, pp 224
29. Popot MA, Boyer S, Michel S, Garcia P, Bonnaire Y (2004) Approaches to the detection of drugs in horse faeces. In: Albert PH, Morton T, Wade JF (eds) 15th International Conference of Racing Analysts and Veterinarians. R&W Communications, Dubai, United Arab Emirates, pp 481
30. Popot MA, Menaut L, Boyer S, Bonnaire Y, Toutain PL (2007) Spurious urine excretion drug profile in the horse due to bedding contamination and drug recycling: the case of meclofenamic acid. J Vet Pharmacol Ther 30:179-184
31. Singh AK, Gupta S, Barnes A, Carlson JM, Ayers JK (2007) Red blood cell erythropoietin, not plasma erythropoietin, concentrations correlate with changes in hematological indices in horses receiving a single dose of recombinant human erythropoietin by subcutaneous injection. J Vet Pharmacol Ther 30:175-178
32. Smith RL (2000) The zero tolerance approach to doping control in horseracing: a fading illusion? In: Williams RB, Houghton E, Wade JF (eds) 13th International Conference of Racing Analysts and Veterinarians. R&W, Cambridge, UK, pp 9-14
33. Soma LR, Uboh CE (1998) Review of furosemide in horse racing: its effects and regulation. J Vet Pharmacol Ther 21:228-240
34. Spencer WA, Camargo FC, Karpiesiuk W, Hughes C, Stirling KH, Casey PJ, Tobin T (2008) Review of the current status of thresholds/withdrawal time guidelines for therapeutic medications in performance horses. AAEP Proc 54:29-37
35. Sweeney CR, Soma LR (1984) Exercise-induced pulmonary hemorrhage in thoroughbred horses: response to furosemide or hesperidin-citrus bioflavinoids. J Am Vet Med Assoc 185:195-197
36. Tay S, van Iren R, Coleman L, Auer D (1996) Evaluation of ELISA tests for erythropoietin (EPO) detection. In: 11th International Conference of Racing Analysts and Veterinarians. R&W, Queensland, Australia, pp 410-414
37. Thevis M, SchanzerW(2007) Current role of LC-MS(/MS) in doping control. Anal Bioanal Chem 388:1351-1358
38. Thevis M, Kohler M, Schanzer W (2008) New drugs and methods of doping and manipulation. Drug Discov Today 13:59-66
39. Tobin T (1981) Drugs and the performance horse, 1st edn. Charles C Thomas, Springfield, USA pp 488
40. Tobin T, Harkins JD, Lehner AF, Woods WE, Karpiesiuk W, Dirikolu L, Carter W, Boyles J, Sams RA (1998) An overview of analytical/pharmacological relationships and the need for limitations on the sensitivity of testing for certain agents. In: Laviolette B, Koupai-Abyazani (eds) Proceedings of the 12th International Conference of Racing Analysts and Veterinarians. R&W, Vancouver, British Columbia, Canada, pp 210-216
41. Tobin T, Harkins JD, Sams RA (1999) Testing for therapeutic medications: analytical/pharmacological relationships and limitations' on the sensitivity of testing for certain agents. J Vet Pharmacol Ther 22:220-233
42. Toutain PL (2009) How to extrapolate a withdrawal time from an EHLSC published detection time: a Monte Carlo simulation appraisal. Equine Vet J (in press)
43. Toutain PL, Lassourd V (2002a) Pharmacokinetic/pharmacodynamic approach to assess irrelevant plasma or urine drug concentrations in postcompetition samples for drug control in the horse. Equine Vet J 34:242-249
44. Toutain PL, Lassourd V (2002b) Pharmacokinetics/pharmacodynamic assessment of irrelevant drug concentrations in horse plasma or urine for a selection of drugs. In: Hill D, Hill W (eds) 14th International Conference of Racing Analysts and Veterinarians. R&W, Orlando, Florida, USA, pp 19-27
45. Van Eeno P, Delbeke FT (2003) Chromatographic and mass spectrometric criteria in doping and related areas. In: Schanzer W, Geyer H, Gotzmann A, Mareck U (eds) Recent advances in doping analysis. Sport and Buch Strauss, Köln, pp 149-159
46. Wennerlund I, Ingvast-Larsson C, Kallings P, Fredriksson E, Bondesson U (2000) Pharmacokinetics and urinary excretion of naproxen after repeated oral administration. In: Williams RB, Houghton E, Wade JF (eds) 13th International Conference of Racing Analysts and Veterinarians. R&W, Cambridge, UK, pp 195-200
47. Yamada M, Kinoshita K, Kurosawa M et al (2007) Analysis of exogenous nandrolone metabolite in horse urine by gas chromatography/combustion/carbon isotope ratio mass spectrometry. J Pharm Biomed Anal 45:654-658
48. Zawadzkas XA, Sides RH, Bayly WM (2006) Is improved high speed performance following furosemide administration due to diuresis-induced weight loss or reduced severity of exerciseinduced pulmonary haemorrhage? Equine Vet J (Suppl 36):291-292